top of page

Dianthus Therapeutics made waves in September when it announced data from its lead program claseprubart in generalized Myasthenia Gravis - CEO Marino Garcia walks us through the program and data

  • Dec 15, 2025
  • 1 min read

He describes the asset, which has an extended half life and is designed to only inhibit the active form of C1s, and contrasts it with other medicines on the market today. Plus, the rationale for in-licensing a bispecific fusion protein that targets BDCA2 and BAFF/APRIL.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page